Rankings
▼
Calendar
ACAD Q4 2022 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena
ACAD
ACADIA Pharmaceuticals Inc.
$4B
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$136M
+4.4% YoY
Gross Profit
$134M
98.2% margin
Operating Income
-$46M
-33.7% margin
Net Income
-$42M
-30.6% margin
EPS (Diluted)
$-0.26
QoQ Revenue Growth
+4.4%
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$24M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$588M
Total Liabilities
$187M
Stockholders' Equity
$400M
Cash & Equivalents
$115M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$136M
$131M
+4.4%
Gross Profit
$134M
$128M
+4.6%
Operating Income
-$46M
-$45M
-3.1%
Net Income
-$42M
-$43M
+3.2%
← FY 2022
All Quarters
Q1 2023 →